Anvisa approves the emergency use of antibodies for Covid-19 treatment
The indication for use is for mild and moderate Covid-19 cases in adults and pediatric patients (12 years and older) with laboratory-confirmed infection.
- About GRP
- Countries
- Canada’s Health Canada
- United States’ FDA
- Brazil
- Mexico’s COFEPRIS
- Europe’s EMA
- Australia
- China
- Japan’s PMDA
- Korea’s Ministry of Food and Drug Safety (MFDS)
- Taiwan’s Food and Drug Administration (TFDA)
- Singapore’s HSA
- India’s CDSCO
- Services
- Resource Center
- RI Platform
- Japan Regulatory Intelligence (RI)
- China (NMPA) Regulatory Intelligence
- Brazil
- Mexico Regulatory Intelligence (RI)
- USA Regulatory Intelligence (RI)
- Contact Us
Menu